Morepen Laboratories Ltd.
Price
Daily candles · NSEWhat the numbers say
- Low return on equity: 3-year ROE 10.6%.
- Comfortable leverage: debt-to-equity of 0.16.
- Sales growth muted at 8.4% over 3 years.
- Weak cash conversion (CFO/OP 0.27).
- Trades above its industry P/E (68.0 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Morepen strengthens integrated CDMO capabilities with first U.S. ANDA submission
The company has submitted ANDA to USFDA for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths
- Morepen Lab expands reactor capacity for API, CDMO
The company has completed the first phase of its manufacturing capacity expansion program
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 1,806 | 1,812 | 1,690 | 1,418 | 1,547 |
| Other income | 21 | 18 | 14 | 6 | 20 |
| Total Income | 1,827 | 1,830 | 1,704 | 1,424 | 1,567 |
| Expenditure | 1,680 | 1,638 | 1,532 | 1,338 | 1,410 |
| Operating Profit | 147 | 192 | 173 | 86 | 157 |
| Interest | 16 | 8 | 4 | 2 | 2 |
| Depreciation | 36 | 29 | 33 | 28 | 28 |
| Profit before tax | 120 | 155 | 135 | 56 | 127 |
| Tax | 24 | 37 | 39 | 17 | 25 |
| Net Profit | 96 | 118 | 97 | 39 | 102 |
| EPS (₹) | 1.73 | 2.20 | 1.88 | 0.77 | 2.26 |
| Net margin % | 5.3 | 6.5 | 5.7 | 2.7 | 6.6 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 110 | 110 | 102 | 102 | 96 |
| Reserves | 1,137 | 1,047 | 745 | 651 | 457 |
| Net worth | 1,246 | 1,156 | 847 | 753 | 552 |
| Total sources | 1,429 | 1,270 | 889 | 787 | 611 |
| Net block | 513 | 489 | 307 | 267 | 252 |
| Capital work in progress | 22 | 28 | 24 | 17 | 14 |
| Investments | 261 | 180 | 72 | 70 | 70 |
| Inventory | 272 | 300 | 249 | 229 | 276 |
| Debtors | 333 | 325 | 325 | 263 | 251 |
| Cash & bank | 69 | 49 | 52 | 56 | 46 |
| Book value (₹) | 22.75 | 21.10 | 16.58 | 14.73 | 11.56 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 33 | 32 | 73 | -91 | -60 |
| From investing | -123 | -322 | -83 | -47 | -32 |
| From financing | 97 | 300 | 5 | 144 | 66 |
| Net change in cash | 7 | 10 | -5 | 6 | -26 |
| Free cash flow | -91 | -289 | -10 | -138 | -92 |
| Closing cash | 31 | 27 | 17 | 22 | 16 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 10.2 | 15.5 | 16.8 | 8.4 | 24.9 |
| ROE % | 8.0 | 11.8 | 12.1 | 5.9 | 21.8 |
| PAT margin % | 5.3 | 6.5 | 5.7 | 2.7 | 6.6 |
| EBIT margin % | 7.6 | 9.0 | 8.2 | 4.1 | 8.3 |
| Debt / equity | 0.16 | 0.07 | 0.03 | 0.03 | 0.03 |
| Current ratio | 2.37 | 2.32 | 2.21 | 2.35 | 1.61 |
| Interest cover | 8.31 | 19.59 | 37.50 | 29.15 | 53.22 |
| Sales growth % | -0.3 | 7.2 | 19.3 | -8.4 | 30.2 |
| Dividend per share (₹) | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 |
| Payout % | 11.6 | 9.3 | 0.0 | 0.0 | 0.0 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Morepen Laboratories Ltd. (MOREPENLAB) last traded at ₹117.67 on the NSE, up +1.95% on the session. Prices on this page are indicative and for information only.
Morepen Laboratories Ltd. has traded between ₹33.05 and ₹150.70 over the last 52 weeks on the NSE.
Morepen Laboratories Ltd. has a market capitalisation of about ₹6,447 crore.
Morepen Laboratories Ltd. trades at a P/E of 68.0, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for MOREPENLAB from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Morepen Laboratories Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in